Trailing GSK, AstraZeneca offers an encouraging look at PhIII data for three-in-one COPD inhaler
AstraZeneca $AZN started the day with news that its three-in-one chronic obstructive pulmonary disease inhaler has turned out positive top-line results in a Phase III trial. But they may have arrived too late with too little to directly challenge GlaxoSmithKline in the field.
Compared with dual combination therapies, twice-daily doses of PT010 — which contains budesonide, glycopyrronium and formoterol fumarate — demonstrated statistically significant improvement in eight out of nine lung function primary endpoints, the UK pharma giant said, without providing numbers. A formulation of glycopyrronium and formoterol fumarate makes Bevespi Aerosphere, currently approved for COPD.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.